Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
10
12
2021
accepted:
14
01
2022
pubmed:
20
1
2022
medline:
22
4
2022
entrez:
19
1
2022
Statut:
ppublish
Résumé
Booster vaccination with messenger RNA (mRNA) vaccines has been offered to adults in England starting on 14 September 2021. We used a test-negative case-control design to estimate the relative effectiveness of a booster dose of BNT162b2 (Pfizer-BioNTech) compared to only a two-dose primary course (at least 175 days after the second dose) or unvaccinated individuals from 13 September 2021 to 5 December 2021, when Delta variant was dominant in circulation. Outcomes were symptomatic coronavirus disease 2019 (COVID-19) and hospitalization. The relative effectiveness against symptomatic disease 14-34 days after a BNT162b2 or mRNA-1273 (Moderna) booster after a ChAdOx1-S (AstraZeneca) and BNT162b2 as a primary course ranged from around 85% to 95%. Absolute vaccine effectiveness ranged from 94% to 97% and was similar in all age groups. Limited waning was seen 10 or more weeks after the booster. Against hospitalization or death, absolute effectiveness of a BNT162b2 booster ranged from around 97% to 99% in all age groups irrespective of the primary course, with no evidence of waning up to 10 weeks. This study provides real-world evidence of substantially increased protection from the booster vaccine dose against mild and severe disease irrespective of the primary course.
Identifiants
pubmed: 35045566
doi: 10.1038/s41591-022-01699-1
pii: 10.1038/s41591-022-01699-1
pmc: PMC9018410
doi:
Substances chimiques
COVID-19 Vaccines
0
mRNA Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
831-837Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
© 2022. Crown.
Références
Lopez Bernal, J. et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. N. Engl. J. Med. 385, 585–594 (2021).
doi: 10.1056/NEJMoa2108891
pubmed: 34289274
Ismail, S. A. et al. Effectiveness of BNT162b2 mRNA and ChAdOx1 adenovirus vector COVID-19 vaccines on risk of hospitalisation among older adults in England: an observational study using surveillance data.Lancet Infect. Dis. 21, 1539–1548 (2021).
doi: 10.1016/S1473-3099(20)30882-3
Vasileiou, E. et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet 397, 1646–1657 (2021).
doi: 10.1016/S0140-6736(21)00677-2
pubmed: 33901420
pmcid: 8064669
Pritchard, E. et al. Impact of vaccination on SARS-CoV-2 cases in the community: a population-based study using the UK’s COVID-19 infection survey. Nat. Med. 27, 370–1378 (2021).
doi: 10.1038/s41591-021-01410-w
Hyams, C. et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study.Lancet Infect. Dis. 21, 1539–1548 (2021).
doi: 10.1016/S1473-3099(21)00330-3
pubmed: 34174190
pmcid: 8221734
Lopez Bernal, J. et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 373, n1088 (2021).
doi: 10.1136/bmj.n1088
pubmed: 33985964
Pouwels, K. B. et al. Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat. Med. 27, 2127–2135 (2021).
doi: 10.1038/s41591-021-01548-7
pubmed: 34650248
pmcid: 8674129
Andrews, N. et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N. Engl. J. Med. 386, 340–350 (2022).
doi: 10.1056/NEJMoa2115481
pubmed: 35021002
Goldberg, Y. et al. Waning immunity of the BNT162b2 vaccine: a nationwide study from Israel.N. Engl. J. Med. 385, e85 (2021).
doi: 10.1056/NEJMoa2114228
pubmed: 34706170
Alasdair, P. S. et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.Lancet 398, 2258–2276 (2021).
doi: 10.1016/S0140-6736(21)02717-3
JCVI statement regarding a COVID-19 booster vaccine programme for winter 2021 to 2022 (Department of Health and Social Care, 2021).
Arbel, R. et al. BNT162b2 vaccine booster and mortality due to COVID-19. N. Engl. J. Med. 385, 2413–2420 (2021).
doi: 10.1056/NEJMoa2115624
pubmed: 34879190
Lopez Bernal, J. et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 373, n1088 (2021).
doi: 10.1136/bmj.n1088
pubmed: 33985964
Amirthalingam, G. et al. Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. Nat. Commun. 12, 7217 (2021).
doi: 10.1038/s41467-021-27410-5
pubmed: 34893611
pmcid: 8664823
Abu-Raddad, L. J. et al. Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar. JAMA. 326, 1930–1939 (2021).
doi: 10.1001/jama.2021.19623
pubmed: 34724027
Bar-On, Y. M. et al. Protection of BNT162b2 vaccine booster against COVID-19 in Israel. N. Engl. J. Med. 385, 1393–1400 (2021).
doi: 10.1056/NEJMoa2114255
pubmed: 34525275
Israel, A. et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. BMJ 375, e067873 (2021).
doi: 10.1136/bmj-2021-067873
pubmed: 34819275
Mizrahi, B. et al. Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. Nat. Commun. 12, 6379 (2021).
doi: 10.1038/s41467-021-26672-3
pubmed: 34737312
pmcid: 8569006
Barda, N. et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.Lancet 398, 2093–2100 (2021).
doi: 10.1016/S0140-6736(21)02249-2
pubmed: 34756184
pmcid: 8555967